Antibodies against analogs of brain-derived neurotrophic factor
AssigneeAmgen Inc.
InventorsThomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
Life of this patent
Estimating the term…
Abstract
The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
Claims38
A polypeptide analog of a cationic polypeptide wherein the analog has an amino acid sequence that differs from the native sequence of the original polypeptide by one or more amino acid residues, or by chemical modification of one or more amino acid residues in the native sequence, such that the isoelectric point is lower and the in vivo circulating life and/or absorption is increased for the analog relative to those same properties in the unmodified cationic polypeptide.
A DNA molecule encoding a polypeptide analog of a cationic polypeptide wherein the analog has an amino acid sequence that differs from the native sequence of the original polypeptide by one or more amino acid residues, or by chemical modification of one or more amino acid residues in the native sequence, such that the isoelectric point is lower and the in vivo circulating life and/or absorption is increased for the analog relative to those same properties in the unmodified cationic polypeptide.
A process for the production of a polypeptide analog of a cationic polypeptide, wherein the analog has an amino acid sequence that differs from the native sequence of the original polypeptide by one or more amino acid residues, such that the isoelectric point is lower and the in vivo circulating life and/or absorption is increased for the analog relative to those same properties in the unmodified cationic polypeptide, said process comprising culturing under suitable nutrient conditions a prokaryotic or eukaryotic host cell transformed or transfected with an expression vector comprising a DNA molecule encoding said polypeptide in a manner allowing the host cell to express the polypeptide, and optionally isolating the polypeptide product of the expression.
Dependencies are inferred from the claim text.